Utility and limitations of sp600125 an inhibitor of stress-responsive c-jun n-terminal kinase

Shuhei Tanemura, Tokiwa Yamasaki, Toshiaki Katada, Hiroshi Nishina

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) belongs to the mitogen-activated protein kinase (MAPK) family and plays an important role in many biological contexts. JNK is deeply involved in several serious human disorders, including inflammation, obesity, diabetes, neuronal disease and cancer. Accordingly, JNK has been recognized as an appropriate target for the treatment of these diseases, and much effort has been expended over the past 15 years to isolate JNK inhibitors that can inactivate this kinase. In 2001, the compound SP600125 was reported as the first JNK-specific inhibitor. Many researchers have subsequently employed SP600125 in in vitro and in vivo models to evaluate whether certain disease-associated events are JNK-dependent. Indeed, more than 1300 studies citing the use of SP600125 as a JNK inhibitor in cell cultures and animal models have been reported. However, although SP600125 has been employed successfully to inhibit JNK in several situations, there have been questions about its specificity for JNK. SP600125 can bind to a broad range of protein kinases and inhibit some of them with similar or greater potency than JNK, confirming that many additional kinases may be targets of SP600125. In this article, we review both the usefulness of SP60125 as a JNK inhibitor and the limitations to its specificity.

Original languageEnglish
Pages (from-to)26-33
Number of pages8
JournalCurrent Enzyme Inhibition
Volume6
Issue number1
DOIs
Publication statusPublished - 2010 Feb 1
Externally publishedYes

Fingerprint

Phosphotransferases
Protein Kinases
JNK Mitogen-Activated Protein Kinases
Medical problems
Heat-Shock Proteins
Mitogen-Activated Protein Kinases
Cell culture
anthra(1,9-cd)pyrazol-6(2H)-one
Animals
Animal Models
Cell Culture Techniques
Obesity
Research Personnel
Inflammation
Neoplasms

Keywords

  • Allergy
  • JNK
  • Kinase inhibitor
  • LgE
  • MAP kinase
  • Mast cell
  • PI3K
  • SP600125

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Drug Discovery

Cite this

Utility and limitations of sp600125 an inhibitor of stress-responsive c-jun n-terminal kinase. / Tanemura, Shuhei; Yamasaki, Tokiwa; Katada, Toshiaki; Nishina, Hiroshi.

In: Current Enzyme Inhibition, Vol. 6, No. 1, 01.02.2010, p. 26-33.

Research output: Contribution to journalReview article

Tanemura, Shuhei ; Yamasaki, Tokiwa ; Katada, Toshiaki ; Nishina, Hiroshi. / Utility and limitations of sp600125 an inhibitor of stress-responsive c-jun n-terminal kinase. In: Current Enzyme Inhibition. 2010 ; Vol. 6, No. 1. pp. 26-33.
@article{8aeda2ef23bb43f08621d35032779a17,
title = "Utility and limitations of sp600125 an inhibitor of stress-responsive c-jun n-terminal kinase",
abstract = "Stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) belongs to the mitogen-activated protein kinase (MAPK) family and plays an important role in many biological contexts. JNK is deeply involved in several serious human disorders, including inflammation, obesity, diabetes, neuronal disease and cancer. Accordingly, JNK has been recognized as an appropriate target for the treatment of these diseases, and much effort has been expended over the past 15 years to isolate JNK inhibitors that can inactivate this kinase. In 2001, the compound SP600125 was reported as the first JNK-specific inhibitor. Many researchers have subsequently employed SP600125 in in vitro and in vivo models to evaluate whether certain disease-associated events are JNK-dependent. Indeed, more than 1300 studies citing the use of SP600125 as a JNK inhibitor in cell cultures and animal models have been reported. However, although SP600125 has been employed successfully to inhibit JNK in several situations, there have been questions about its specificity for JNK. SP600125 can bind to a broad range of protein kinases and inhibit some of them with similar or greater potency than JNK, confirming that many additional kinases may be targets of SP600125. In this article, we review both the usefulness of SP60125 as a JNK inhibitor and the limitations to its specificity.",
keywords = "Allergy, JNK, Kinase inhibitor, LgE, MAP kinase, Mast cell, PI3K, SP600125",
author = "Shuhei Tanemura and Tokiwa Yamasaki and Toshiaki Katada and Hiroshi Nishina",
year = "2010",
month = "2",
day = "1",
doi = "10.2174/157340810790712023",
language = "English",
volume = "6",
pages = "26--33",
journal = "Current Enzyme Inhibition",
issn = "1573-4080",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

TY - JOUR

T1 - Utility and limitations of sp600125 an inhibitor of stress-responsive c-jun n-terminal kinase

AU - Tanemura, Shuhei

AU - Yamasaki, Tokiwa

AU - Katada, Toshiaki

AU - Nishina, Hiroshi

PY - 2010/2/1

Y1 - 2010/2/1

N2 - Stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) belongs to the mitogen-activated protein kinase (MAPK) family and plays an important role in many biological contexts. JNK is deeply involved in several serious human disorders, including inflammation, obesity, diabetes, neuronal disease and cancer. Accordingly, JNK has been recognized as an appropriate target for the treatment of these diseases, and much effort has been expended over the past 15 years to isolate JNK inhibitors that can inactivate this kinase. In 2001, the compound SP600125 was reported as the first JNK-specific inhibitor. Many researchers have subsequently employed SP600125 in in vitro and in vivo models to evaluate whether certain disease-associated events are JNK-dependent. Indeed, more than 1300 studies citing the use of SP600125 as a JNK inhibitor in cell cultures and animal models have been reported. However, although SP600125 has been employed successfully to inhibit JNK in several situations, there have been questions about its specificity for JNK. SP600125 can bind to a broad range of protein kinases and inhibit some of them with similar or greater potency than JNK, confirming that many additional kinases may be targets of SP600125. In this article, we review both the usefulness of SP60125 as a JNK inhibitor and the limitations to its specificity.

AB - Stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) belongs to the mitogen-activated protein kinase (MAPK) family and plays an important role in many biological contexts. JNK is deeply involved in several serious human disorders, including inflammation, obesity, diabetes, neuronal disease and cancer. Accordingly, JNK has been recognized as an appropriate target for the treatment of these diseases, and much effort has been expended over the past 15 years to isolate JNK inhibitors that can inactivate this kinase. In 2001, the compound SP600125 was reported as the first JNK-specific inhibitor. Many researchers have subsequently employed SP600125 in in vitro and in vivo models to evaluate whether certain disease-associated events are JNK-dependent. Indeed, more than 1300 studies citing the use of SP600125 as a JNK inhibitor in cell cultures and animal models have been reported. However, although SP600125 has been employed successfully to inhibit JNK in several situations, there have been questions about its specificity for JNK. SP600125 can bind to a broad range of protein kinases and inhibit some of them with similar or greater potency than JNK, confirming that many additional kinases may be targets of SP600125. In this article, we review both the usefulness of SP60125 as a JNK inhibitor and the limitations to its specificity.

KW - Allergy

KW - JNK

KW - Kinase inhibitor

KW - LgE

KW - MAP kinase

KW - Mast cell

KW - PI3K

KW - SP600125

UR - http://www.scopus.com/inward/record.url?scp=77951082847&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951082847&partnerID=8YFLogxK

U2 - 10.2174/157340810790712023

DO - 10.2174/157340810790712023

M3 - Review article

AN - SCOPUS:77951082847

VL - 6

SP - 26

EP - 33

JO - Current Enzyme Inhibition

JF - Current Enzyme Inhibition

SN - 1573-4080

IS - 1

ER -